How to Buy Dishman Carbogen Amcis Ltd Shares?
You can easily buy the stocks/shares of Dishman Carbogen Amcis Ltd (DCAL) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Dishman Carbogen Amcis Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of DCAL as on 15th May 2025 is ₹215.78What is the return on Dishman Carbogen Amcis Ltd share?
The past returns of Dishman Carbogen Amcis Ltd (DCAL) share are- Past 1 week: N/A
- Past 1 month: -94.37
- Past 3 months: 33.19
- Past 6 months: -0.03
- Past 1 year: 60.91
- Past 3 years: 126.54
- Past 5 years: 121.43
What is the Dividend yield % on Dishman Carbogen Amcis Ltd share?
The current dividend yield of Dishman Carbogen Amcis Ltd (DCAL) is N/AWhat is the Market Cap of Dishman Carbogen Amcis Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dishman Carbogen Amcis Ltd (DCAL) is ₹4377.08Cr as of 15th May 2025What is the 52 Week High and Low of Dishman Carbogen Amcis Ltd?
The 52-week high and low of Dishman Carbogen Amcis Ltd (DCAL) is ₹307.98 and ₹155.05.What is the PE and PB ratio of Dishman Carbogen Amcis Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Dishman Carbogen Amcis Ltd are 1350.95 and 0.78 respectively.Which sector does Dishman Carbogen Amcis Ltd belong to?
Dishman Carbogen Amcis Ltd (DCAL) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.What are the peers or stocks similar to Dishman Carbogen Amcis Ltd?
The peers or stocks similar to Dishman Carbogen Amcis Ltd are: and many others.Can't decide whether or not to buy Dishman Carbogen Amcis Ltd?
Worry no more! Login to Tickertape and check out Dishman Carbogen Amcis Ltd (DCAL) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Dishman Carbogen Amcis Ltd?
The 52-week high and low of Dishman Carbogen Amcis Ltd (DCAL) is ₹307.98 and ₹155.05.1. Test Stocks FAQ for Dishman Carbogen Amcis Ltd Shares?
You can easily buy the stocks/shares of Dishman Carbogen Amcis Ltd (DCAL) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Dishman Carbogen Amcis Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of DCAL as on 15th May 2025 is ₹215.78
Dishman Carbogen Amcis Ltd
DCAL Share Price
215.781.34% (+2.85)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
DCAL Performance & Key Metrics
DCAL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 1,350.95 | 0.78 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
DCAL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
DCAL Company Profile
Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing
DIVISLAB
PE Ratio
80.67
80.67
1Y Return
45.14%
45.14%
Buy Reco %
28.57
28.57
SYNGENE
PE Ratio
52.81
52.81
1Y Return
6.24%
6.24%
Buy Reco %
87.50
87.50
AARTIPHARM
PE Ratio
29.43
29.43
1Y Return
48.50%
48.50%
Buy Reco %
—
—
VIMTALABS
PE Ratio
33.92
33.92
1Y Return
105.40%
105.40%
Buy Reco %
—
—
BROOKS
PE Ratio
-37.08
-37.08
1Y Return
52.45%
52.45%
Buy Reco %
—
—
DCAL Sentiment Analysis
DCAL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
DCAL Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
DCAL Stock Growth Drivers
DCAL Stock Growth Drivers
1Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
DCAL Stock Challenges
DCAL Stock Challenges
3Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
DCAL Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
DCAL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
DCAL
DCAL
Income
Balance Sheet
Cash Flow
Annual Normal View
DCAL Income Statement
DCAL Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,739.82 | 1,740.48 | 2,112.42 | 2,088.06 | 1,950.48 | 2,184.11 | 2,440.69 | 2,643.98 | 2,733.18 | 2,735.22 | ||||||||||
Raw Materials | 329.58 | 402.19 | 378.01 | 476.38 | 434.77 | 460.50 | 630.40 | 601.21 | 2,260.67 | 2,262.71 | ||||||||||
| Power & Fuel Cost | 49.47 | 48.33 | 56.14 | 60.26 | 41.87 | 62.73 | 87.83 | 104.31 | ||||||||||||
| Employee Cost | 596.02 | 625.40 | 714.64 | 762.27 | 872.91 | 981.49 | 1,029.86 | 1,208.16 | ||||||||||||
| Selling & Administrative Expenses | 147.69 | 136.29 | 190.73 | 124.58 | 113.81 | 147.71 | 197.66 | 205.53 | ||||||||||||
| Operating & Other expenses | 138.47 | 37.23 | 167.18 | 122.55 | 196.60 | 171.53 | 183.12 | 216.20 | ||||||||||||
EBITDA | 478.59 | 491.04 | 605.72 | 542.02 | 290.52 | 360.15 | 311.82 | 308.57 | 472.51 | 472.51 | ||||||||||
| Depreciation/Amortization | 213.50 | 211.42 | 240.38 | 282.87 | 307.94 | 307.59 | 280.72 | 310.86 | 293.74 | 293.74 | ||||||||||
| PBIT | 265.09 | 279.62 | 365.34 | 259.15 | -17.42 | 52.56 | 31.10 | -2.29 | 178.77 | 178.77 | ||||||||||
| Interest & Other Items | 49.01 | 48.83 | 56.55 | 61.95 | 47.61 | 56.81 | 85.69 | 119.97 | 159.46 | 159.46 | ||||||||||
| PBT | 216.08 | 230.79 | 308.79 | 197.20 | -65.03 | -4.25 | -54.59 | -122.26 | 19.31 | 19.31 | ||||||||||
| Taxes & Other Items | 70.65 | 76.22 | 98.46 | 38.69 | 100.10 | -22.26 | -24.79 | 31.19 | 16.07 | 16.07 | ||||||||||
| Net Income | 145.43 | 154.57 | 210.33 | 158.51 | -165.13 | 18.01 | -29.80 | -153.45 | 3.24 | 3.24 | ||||||||||
| EPS | — | 19.15 | 13.03 | 9.96 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | 0.21 | ||||||||||
| DPS | 1.20 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | — | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DCAL Company Updates
FY 2025FY 2025
Investor Presentation
May 22PDF
Nov 13PDF
DCAL Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
DCAL Past Performance & Peer Comparison
DCAL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation-basic on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dishman Carbogen Amcis Ltd | 1,350.95 | 0.78 | — |
| Divi's Laboratories Ltd | 80.67 | 13.02 | 0.45% |
| Syngene International Ltd | 52.81 | 6.15 | 0.19% |
| Aarti Pharmalabs Ltd | 29.43 | 4.56 | 0.57% |
DCAL Stock Price Comparison
Compare DCAL with any stock or ETFCompare DCAL with any stock or ETF
DCAL
DCAL Holdings
DCAL Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
DCAL Promoter Holdings Trend
DCAL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
DCAL Institutional Holdings Trend
DCAL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
DCAL Shareholding Pattern
DCAL Shareholding Pattern
DCAL Shareholding History
DCAL Shareholding History
Foreign Institutions
Mutual Funds Invested in DCAL
Mutual Funds Invested in DCAL
No mutual funds holding trends are available
Top 5 Mutual Funds holding Dishman Carbogen Amcis Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8270% | Percentage of the fund’s portfolio invested in the stock 0.73% | Change in the portfolio weight of the stock over the last 3 months 0.73% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 67/87 (-30) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0942% | Percentage of the fund’s portfolio invested in the stock 0.17% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 224/323 (-10) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.11% | Change in the portfolio weight of the stock over the last 3 months 0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 69/102 (-51) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing DCAL stock
smallcases containing DCAL stock
Looks like this stock is not in any smallcase yet.
DCAL Events
DCAL Events
DCAL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DCAL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
DCAL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DCAL has not given any dividends in last 5 years
DCAL Upcoming Dividends
DCAL Upcoming Dividends
No upcoming dividends are available
DCAL Past Dividends
DCAL Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2019
Final
Final | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Sep 12, 2019
DCAL Stock News & Opinions
DCAL Stock News & Opinions
Articles & Videos
Corporate
Carbogen Amic AG to co-invest in its manufacturing sites in Switzerland
Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including: ' Aarau site: installation of 850-litre reactors and 0.4 m' agitated filter dryers with supporting equipment. Completion is expected by Q1 2027. ' Neuland site: installation of 850-litre reactors and 0.4 m' agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027. This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth. Powered by Capital Market - Live
1 week agoCapital Market - Live
Spotlight
Dishman Carbogen spurts after turnaround Q4 outcome
Consolidated net sales rose 9.41% year-on-year to Rs 716.34 crore in Q4 March 2025. Pre-tax profit before exxceptional items stood at Rs 39.45 crore in Q4 FY25 as against pre-tax loss before exceptional items of Rs 46.11 crore in Q4 FY24. For the full year, the company reported net profit of Rs 3.24 crore in the year ended March 2025 as against net loss of Rs 153.45 crore in the year ended March 2024. Net sales rose 3.66% YoY to Rs 2711.50 crore in the year ended March 2025. Pre-tax profit before exceptional items stood at Rs 37.42 crore in FY25 as against pre-tax loss before exceptional items of Rs 116.12 crore in FY24. During the quarter and year ended 31 March 2025, certain subsidiaries discarded some of their inventories, which was not expected to be usable for projects that the company estimated to undertake in near to mid-term. The loss on account of these impairment were Rs 0.77 crore and Rs 7.13 crore respectively for the quarter and year. Further, during the quarter ended 31 March 2025, one of the subsidiaries Carbogen Amcis AG, had impaired expenditure incurred for capex project. The loss on account of this impairment was Rs 10.98 crore for the quarter and the year. The company's consolidated net cash from operating activities stood at Rs 375.23 crore in FY25, lower than Rs 379.43 crore in FY24. Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It provides a range of development and manufacturing solutions at locations in Europe, China and in India. Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports consolidated net profit of Rs 43.09 crore in the March 2025 quarter
Net profit of Dishman Carbogen Amcis reported to Rs 43.09 crore in the quarter ended March 2025 as against net loss of Rs 69.92 crore during the previous quarter ended March 2024. Sales rose 9.41% to Rs 716.34 crore in the quarter ended March 2025 as against Rs 654.71 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 3.24 crore in the year ended March 2025 as against net loss of Rs 153.45 crore during the previous year ended March 2024. Sales rose 3.66% to Rs 2711.50 crore in the year ended March 2025 as against Rs 2615.77 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales716.34654.71 9 2711.502615.77 4 OPM %21.329.57 -17.2910.95 - PBDT118.5438.89 205 331.16194.74 70 PBT39.45-46.11 LP 37.42-116.12 LP NP43.09-69.92 LP 3.24-153.45 LP Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports standalone net loss of Rs 7.37 crore in the March 2025 quarter
Net Loss of Dishman Carbogen Amcis reported to Rs 7.37 crore in the quarter ended March 2025 as against net loss of Rs 31.12 crore during the previous quarter ended March 2024. Sales declined 4.64% to Rs 106.10 crore in the quarter ended March 2025 as against Rs 111.26 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 9.87 crore in the year ended March 2025 as against net loss of Rs 76.41 crore during the previous year ended March 2024. Sales rose 22.14% to Rs 399.84 crore in the year ended March 2025 as against Rs 327.35 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales106.10111.26 -5 399.84327.35 22 OPM %19.3510.40 -17.952.08 - PBDT4.69-7.51 LP 34.371.66 1970 PBT-11.41-33.63 66 -30.83-99.95 69 NP-7.37-31.12 76 -9.87-76.41 87 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to hold board meeting
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 21 May 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Dishman Carbogen Amcis' Shanghai facility clears China regulatory compliance
Dishman Carbogen Amcis announced that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China's National Medical Products Administration (NMPA). The NMPA approval followed a rigorous review focused on GMP compliance and operational readiness. The Shanghai site successfully met all regulatory expectations, reflecting the maturing of its operations and the strength of its quality systems. This milestone marks a pivotal step in CARBOGEN AMCIS' expansion in China and reinforces its commitment to customers in the region. Located in the Shanghai Chemical Industry Park (SCIP), the 40,000m' site is a fully self-supporting facility equipped for early-phase research and development, pilot scale production and commercial GMP manufacture. Its services range from raw materials to APIs, including high potency material handling and micronization. With equipment in four segregated units and reactor capacities from 50 to 6,300 litres, the facility is built for flexibility, efficiency and scalability. The site employs over 140 people and brings together an international team of specialists whose expertise, combined with advanced infrastructure, enables the delivery of tailored, scalable solutions to customers worldwide. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Dishman Carbogen Amcis receives affirmation in credit ratings
Dishman Carbogen Amcis has received affirmation in credit ratings from India Ratings and Research at IND A+; Stable/ IND A1+ for various debt facilities availed by the company. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis allots NCDs aggregating Rs 50 cr
Dishman Carbogen Amcis has allotted 5,000 Rated, Listed, Senior, Secured, Redeemable, Taxable Non-Convertible Debentures of face value of Rs. 1,00,000 each, aggregating to Rs 50 crore on private placement basis. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to hold board meeting
Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 12 March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports consolidated net profit of Rs 4.63 crore in the December 2024 quarter
Net profit of Dishman Carbogen Amcis reported to Rs 4.63 crore in the quarter ended December 2024 as against net loss of Rs 59.63 crore during the previous quarter ended December 2023. Sales rose 4.80% to Rs 682.34 crore in the quarter ended December 2024 as against Rs 651.09 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales682.34651.09 5 OPM %20.546.31 - PBDT96.9814.08 589 PBT25.01-66.29 LP NP4.63-59.63 LP Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.59%, vs industry avg of 4.56%
Over the last 5 years, market share decreased from 16.86% to 14.97%